| DB ID | MyCo_5531 |
| Title | Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms |
| Year | 2012 |
| PMID | 23284710 |
| Fungal Diseases involved | Pneumonia |
| Associated Medical Condition | HIV-AIDS-Respiratory Symptoms |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The study was approved by the institutional review boards at University of California San Francisco, University of Cincinnati, Mulago Hospital, Makerere University, and the Uganda National Council for Science and Technology. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Lung Tissue Homogenate |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IgM-MsgC8 |
| Biomarker Full Name | Immunoglobulin M-Major surface glycoprotein C8 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Uganda |
| Cohort | Between May 2007 and June 2008, we screened consecutive adults (>18 years old) admitted to Mulago Hospital in Kampala, Uganda. Those with cough ³2 weeks but, <6 months in duration were eligible for the study. Those on anti-TB therapy or with evidence of heart failure at the time of screening were excluded. We conducted a prospective study of 550 patients, both HIV-positive (n = 467) and HIV-negative (n = 83), hospitalized with cough ³2 weeks in Kampala, Uganda, to evaluate the association between HIV status, CD4 cell count, and other clinical predictors and antibody responses to P. jirovecii. |
| Cohort No. | 550 |
| Age Group | None |
| P Value | p=0.02 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii continues to be an important cause of pneumonia in immunosuppressed individuals, especially in those with HIV infection who do not have access to or cannot tolerate antiretroviral therapy (ARV) or Pneumocystis prophylaxis. Because Pneumocystis is not easily cultured, serologic studies have been particularly important in providing insights into Pneumocystis exposure, transmission, disease activity and immune responses. For instance, through these studies we have found that healthcare workers with direct patient contact have higher antibody levels to P. jirovecii than staff without patient contact, suggesting potential person-to-person transmission. We have also found that the serologic responses to P. jirovecii are dependent on geographic location, suggesting geographic variation in the level of P. jirovecii exposure, exposure to different strains of P. jirovecii, or differences in host immunologic responses to Pneumocystis in varied human populations. |
| Technique | PCR |
| Analysis Method | PCR Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, PCR |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
